EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Impact of Metformin therapy on miR-9, miR-223, and miR-132 and inflammasome-related gen expression in obese and non-obes PCOS patients: A comparative study with healthy controls

Seyed Alireza Mirjalili, Seyed Mehdi Kalantar, Fateme Montazeri, Reyhaneh Azizi, Elham Hosseini, Fateme Zare, Samira Asgharzade, Korosh Ashrafi Dehkordi iD

PLOS One · 2025

DOI: 10.1371/journal.pone.0335280 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift PLOS One, 2025. Verfasst von Seyed Alireza Mirjalili und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Medicine, School of Advanced Technologies, Shahrekord University of Medical Sciences, Shahrekord, Iran. Hauptthemen laut MEDLINE: MicroRNAs, Metformin, Polycystic Ovary Syndrome, Obesity. Die Arbeit nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shahrekord University of Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Polycystic Ovary Syndrome (PCOS) is a common endocrine and metabolic disorder characterized by chronic inflammation, insulin resistance, and hormonal imbalances, often leading to infertility and metabolic dysfunction. Metformin, an insulin-sensitizing agent, has shown potential to improve these conditions. This study investigated the impact of metformin on inflammasome-regulating microRNAs ( miR-9, miR-223, miR-132 ) and related genes ( IL-1β, IL-18, caspase-1, NLRP3 ) in obese and non-obese PCOS patients compared to healthy controls. Materials and methods In this case-control study, 100 women aged 18–35 were divided into 50 PCOS patients and 50 controls, stratified by BMI (>25 kg/m² and 25 kg/m²) compared to healthy controls (mean ± SD: 0.54 ± 0.07 vs. 1.00 ± 0.11; P < 0.001). Following metformin treatment, miR-223 expression was significantly upregulated (from 0.88 ± 0.06 to 1.21 ± 0.08; P = 0.002). Similarly, the expression levels of IL-1β (2.01 ± 0.31 vs. 1.31 ± 0.23) and NLRP3 (2.12 ± 0.27 vs. 1.38 ± 0.22) decreased significantly post-treatment (P < 0.01). No significant change was observed in miR-132 expression. Overall, metformin modulated the expression profiles of inflammasome-related genes and miRNAs, particularly in obese patients with PCOS.

Conclusion

The findings suggest that metformin modulates inflammation in PCOS by altering microRNA and inflammasome-related gene expression, thereby reducing inflammatory markers such as IL-1β and miR-9, while enhancing miR-132 and miR-223, which may contribute to improved metabolic and inflammatory profiles. These results support the use of metformin as a BMI-tailored therapeutic strategy for PCOS, warranting further research to confirm its long-term effects and mechanisms.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MicroRNAsMetforminPolycystic Ovary SyndromeObesityInflammasomesHypoglycemic AgentsHumansFemaleAdultCase-Control StudiesYoung AdultAdolescentNLR Family, Pyrin Domain-Containing 3 ProteinInterleukin-1betaGene Expression RegulationInterleukin-18

Substanzen

MicroRNAsMetforminInflammasomesNLR Family, Pyrin Domain-Containing 3 ProteinInterleukin-1betaHypoglycemic AgentsInterleukin-18MIRN132 microRNA, humanMIR223, humanMIRN92 microRNA, human

Autor:innen und Institutionen

  • Department of Molecular Medicine, School of Advanced Technologies, Shahrekord University of Medical Sciences, Shahrekord, Iran.
  • Abortion Research Center, Yazd Reproductive Sciences Institute, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
  • Diabetes Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
  • Department of Obstetrics and Gynecology, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran.
  • Reproductive Immunology Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
  • Cellular and Molecular Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord, Iran.

ORCID-Profile: Korosh Ashrafi Dehkordi

Förderung

  • Shahrekord University of Medical Sciences

Zitieren

APA

Mirjalili, S. A., Kalantar, S. M., Montazeri, F., Azizi, R., Hosseini, E., Zare, F., Asgharzade, S., & Ashrafi Dehkordi, K. (2025). Impact of Metformin therapy on miR-9, miR-223, and miR-132 and inflammasome-related gen expression in obese and non-obes PCOS patients: A comparative study with healthy controls. PLOS One. https://doi.org/10.1371/journal.pone.0335280

Vancouver

Mirjalili SA, Kalantar SM, Montazeri F, Azizi R, Hosseini E, Zare F, et al. Impact of Metformin therapy on miR-9, miR-223, and miR-132 and inflammasome-related gen expression in obese and non-obes PCOS patients: A comparative study with healthy controls. PLOS One. 2025. doi:10.1371/journal.pone.0335280

BibTeX
@article{Mirjalili2025,
  author = {Mirjalili, Seyed Alireza and Kalantar, Seyed Mehdi and Montazeri, Fateme and Azizi, Reyhaneh and Hosseini, Elham and Zare, Fateme and Asgharzade, Samira and Ashrafi Dehkordi, Korosh},
  title = {Impact of Metformin therapy on miR-9, miR-223, and miR-132 and inflammasome-related gen expression in obese and non-obes PCOS patients: A comparative study with healthy controls},
  journal = {PLOS One},
  year = {2025},
  doi = {10.1371/journal.pone.0335280}
}
Kostenlos starten →